Overview

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Status:
Completed

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether conversion to everolimus (Zortress®), allowing the elimination or reduction of calcineurin inhibitors, will reduce nephrotoxicity (measured by increased creatinine clearance) and lengthen overall graft (kidney transplant) survival (measured by 2-3 year graft survival).

Phase:

Phase 4

Details

Lead Sponsor:

University of Toledo Health Science Campus

Collaborator:

Novartis Pharmaceuticals

Treatments:

Alemtuzumab
Calcineurin Inhibitors
Everolimus
Sirolimus
Tacrolimus